A randomized, double‐blind phase I/IIa study of intranasal glutathione in Parkinson's disease

Depletion of reduced glutathione is associated with PD and glutathione augmentation has been proposed as a disease‐modifying strategy. The aim of this study was to determine the safety and tolerability of intranasal reduced glutathione in individuals with PD.

[1]  M. Cotelli,et al.  Cerebellar transcranial direct current stimulation in patients with ataxia: A double‐blind, randomized, sham‐controlled study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Ciriolo,et al.  Glutathione: new roles in redox signaling for an old antioxidant , 2014, Front. Pharmacol..

[3]  B. McLaughlin,et al.  Redox modification of proteins as essential mediators of CNS autophagy and mitophagy , 2013, FEBS letters.

[4]  M. Gregório,et al.  Nullity of GSTT1/GSTM1 related to pesticides is associated with Parkinson's disease. , 2013, Arquivos de neuro-psiquiatria.

[5]  Laurie K Mischley,et al.  Safety survey of intranasal glutathione. , 2013, Journal of alternative and complementary medicine.

[6]  T. Dall,et al.  The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.

[7]  M. Gregório,et al.  Nullity of GSTT 1 / GSTM 1 related to pesticides is associated with Parkinson ’ s disease , 2013 .

[8]  Laurie K Mischley,et al.  Glutathione 

Deficiency 

in 

Parkinson ’ s 

 Disease : Intranasal Administration as a Method of Augmentation , 2013 .

[9]  A. Mollica,et al.  Recent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery Systems , 2012, Oxidative medicine and cellular longevity.

[10]  R. Hauser,et al.  Determination of minimal clinically important change in early and advanced Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[11]  Yu Tian Wang,et al.  Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  K. Lyons,et al.  Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[13]  D. Dickson,et al.  Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.

[14]  H. Ren,et al.  [A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients]. , 2008, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[15]  C. Marsden,et al.  Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.

[16]  B. Lauterburg,et al.  The systemic availability of oral glutathione , 2005, European Journal of Clinical Pharmacology.

[17]  J. Piccirillo,et al.  Psychometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome Test (Snot-20) , 2002, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[18]  C. Shaw,et al.  Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death , 1997, Brain Research Reviews.

[19]  G. Rosati,et al.  Reduced intravenous glutathione in the treatment of early parkinson's disease , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  N. Kobrinsky,et al.  Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. , 1996, Cancer investigation.

[21]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[22]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[23]  N. Guo,et al.  Glutathione: New candidate neuropeptide in the central nervous system , 1992, Neuroscience.